Creating innovative ways to test for and treat Alzheimer's
More than 5 million Americans are living with Alzheimer's. That number is expected to grow to 14 million by 2050.
Our research team collaborates with leading scientists from around the world to develop innovative ways to test for and treat Alzheimer's and other neurodegenerative diseases.
Led by Dr. Sid O'Bryant, one of the world's leading experts in blood-based biomarkers of Alzheimer's, the institute (ITR) focuses on precision medicine approaches to brain disease, such as Alzheimer's and Parkinson's diseases, Down syndrome, Dementia with Lewy bodies and others.
The focus on translational research is intended to guide and coordinate research that improves outcomes and accelerates research breakthroughs from lab bench to bedside and enhance the quality of life for patients and their families.
The Health & Aging Brain among Latino Elders Study
A study to determine if underlying causes for Alzheimer's vary between racial and ethnic groups so appropriate treatments can be created.